Vogenx, Inc.

424B4 priced

Price $13.00 · 6,250,000 shares · Gross proceeds $81,250,000

EFFECT effective

CERT inactive

8-A12B effective

S-1/A amended

Price $12.00 · Range $11.00 to $13.00 · 6,250,000 shares

Vogenx, Inc. is conducting an IPO with 6,250,000 shares of common stock offered at an expected price range of $11.00-$13.00 per share. The company has granted underwriters a 45-day option to purchase an additional 937,500 shares. Net proceeds from the offering, estimated at $67.8 million (or $78.2 million if the underwriters' option is fully exercised), will be used for mizagliflozin development, accrued expenses, R&D, and working capital. The company anticipates listing on the Nasdaq Capital Market under the symbol VOGX. Vogenx has incurred significant losses, with an accumulated deficit of $11.3 million as of March 31, 2026, and expects to continue operating at a loss for the foreseeable future.

S-1/A amended

Range $11.00 to $13.00 · 6,250,000 shares

Vogenx, Inc. is conducting an IPO with an offering of 6,250,000 shares of common stock at an expected price range of $11.00-$13.00 per share. The company plans to use net proceeds for development of mizagliflozin, paying accrued expenses, and general corporate purposes. The offering includes an underwriter option to purchase an additional 937,500 shares. The company expects to list on the Nasdaq Capital Market under the symbol VOGX. The filing includes detailed financial projections, including pro forma adjustments for conversions of preferred stock, convertible notes, and warrants, resulting in 13,905,643 shares outstanding post-offering (14,843,143 if the underwriter option is exercised).

S-1 filed

Vogenx, Inc. outlines significant reliance on third-party collaborators and contractors for clinical trials, manufacturing, and product development. The company faces challenges in securing collaborations, regulatory approvals, and managing dependencies on external partners, which could delay product development and commercialization. Key risks include potential failures in third-party performance, manufacturing delays, and difficulties in scaling production. The filing emphasizes the need for substantial capital and the impact of external factors like market consolidation on collaboration opportunities.

DRS/A amended

DRS/A amended

DRS filed